{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2133365_A2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"057-985-325-749-704","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8590,"type":"PATENT","title":"Harvard University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21990,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-04T04:19:00Z","updated":"2022-09-08T02:14:43Z","lastEventDate":"2022-09-08T02:14:43Z"},{"id":11617,"type":"PATENT","title":"Emory University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6117,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8292,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
contacting a population of donor cells from the same mammalian species comprising T cells with antigen presenting cells (APCs) and a pre-selected antigen of interest, wherein the pre-selected antigen is presented by the APCs to the T cells to produce a population of donor activated T cells in the presence of a PD-1 antagonist; and
transplanting a therapeutically effective amount of the population of donor activated T cells into the recipient; and
administering to the recipient the therapeutically effective amount of a PD-1 antagonist,
thereby producing an immune response to the antigen of interest in the mammalian recipient."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The combination of claim 10, wherein the donor and the recipient are human, optionally wherein the donor and the recipient are the same human subject."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The combination of claim 10, comprising transfecting the APCs with an expression vector comprising a nucleic acid encoding the antigen of interest prior to containing the population of cells comprising T cells with the APCs."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The combination of claim 10, further comprising administering to the subject a therapeutically effective amount of an additional compound, optionally wherein said second compound is a vaccine, optionally a therapeutically effective amount of a tumor antigen or nucleotide sequence encoding a tumor antigen."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A combination according to any preceding claim wherein the combination further comprises a vaccine, optionally a therapeutically effective amount of a tumor antigen or a nucleotide encoding a tumor antigen."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A combination according to any one of claims 13 or 14 wherein the tumor antigen is PRAME, WT1, Survivin, cyclin D, cyclin E, proteinase 3 and its peptide PR1, neutrophil elastase, cathepsin G, MAGE, MART, tyrosinase, GP100, NY-Eso-1, herceptin, carcino-embryonic antigen (CEA), or prostate specific antigen (PSA); a tumor antigen derivative peptide having an amino acid sequence of SEQ ID No. 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35; or a nucleotide sequence encoding a tumor antigen derivate peptide having the amino acid sequence of SEQ ID NO. 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35."],"number":15,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}